查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1544104

全球預測與預測測試市場

Predictive and Presymptomatic Testing
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 159 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

到 2030 年，全球預測和預測測試市場將達到 104 億美元

全球預測和預測測試市場預計 2023 年為 55 億美元，預計到 2030 年將達到 104 億美元，在 2023-2030 年分析期間複合年成長率為 9.5%。

美國市場預估成長14億美元，中國複合年成長率12.6%

到 2023 年，美國預測和預測測試市場預計將達到 14 億美元。中國作為世界第二大經濟體，預計2030年市場規模將達24億美元，2023-2030年分析期間複合年成長率為12.6%。其他值得注意的區域市場包括日本和加拿大，在分析期間預計複合年成長率分別為 6.5% 和 7.5%。在歐洲，德國的複合年成長率預計為 7.4%。

全球預測測試和預測測試市場 - 主要趨勢和促進因素總結

預測和預測測試：預測健康風險

預測和預測測試使用基因和其他診斷測試來評估一個人在症狀出現之前患某種特定疾病的風險。這些測試分析 DNA、蛋白質和其他生物標記物，以識別與癌症、心臟病和神經退化性疾病等疾病發生可能性增加相關的突變和其他指標。預測測試通常用於有特定疾病家族病史的人，以便進行早期療育和預防措施，以降低風險或延遲發病。另一方面，症狀前檢測用於確定無症狀性個體是否會患上已知在家族中遺傳的遺傳疾病。這些測試的主要目的是為個人和醫療保健提供者提供有價值的資訊，以指南醫療決策和生活方式的改變，最終改善健康結果。

技術進步如何改進預測和預測測試？

技術的進步極大地提高了預測和預測測試的準確性、可訪問性和範圍。次世代定序儀(NGS) 的進步使得快速且經濟高效地分析基因組的大片段成為可能，從而能夠識別與疾病風險相關的更廣泛的遺傳變異。更敏感和特異性的生物標記的開發提高了我們甚至在症狀出現之前檢測疾病早期跡象的能力。此外，生物資訊學和機器學習演算法的整合增強了對遺傳資料的解釋，提供更準確的風險評估和個人化見解。此外，直接面對消費者的基因檢測服務的興起正在增加預測性檢測的機會，使個人無需傳統的臨床環境即可了解自己的健康風險。這些技術改進擴大了預測和預測測試的用途和影響，使其成為主動醫療保健的寶貴工具。

預測和預測測試的主要用途和好處是什麼？

預測和預測測試應用於醫療保健的各個領域，為加強疾病預防和控制提供了許多好處。在腫瘤學中，預測測試用於識別患有遺傳性癌症的高風險個體，例如與乳癌和卵巢癌相關的 BRCA1/2 突變，從而可以進行早期監測和預防措施。在心臟病學中，基因檢測可以識別與遺傳性高膽固醇症等疾病相關的突變，並指導預防心臟病的干涉措施。在神經病學中，無症狀性檢測對於亨廷頓舞蹈症等疾病有益，早期診斷有助於計劃生育和生活方式選擇。此外，藥物基因組學中還使用預測測試來確定個體對特定藥物的反應，從而製定個人化的治療計劃，以最佳化療效並最大限度地減少副作用。預測和預測測試的主要好處包括能夠在症狀出現之前識別疾病風險，從而實現早期療育、個人化醫療保健和改善患者治療結果。透過提供對個人遺傳傾向的寶貴見解，這些測試支持主動的健康管理和明智的決策。

推動預測測試和預測測試市場成長的因素有哪些？

預測測試和預測測試市場的成長是由多種因素推動的。人們對遺傳學在疾病風險中的作用的認知不斷提高以及對個人化醫療保健的需求不斷增加是重要的促進因素，因為這些測試為指導個體化治療和預防策略提供了有價值的資訊。提高基因檢測準確性、速度和可負擔性的技術進步也推動了市場成長。直接面對消費者的基因檢測服務的擴展，使這些檢測更容易為大眾所接受，進一步推動了需求。此外，對預防性醫療保健和早期疾病檢測的更多關注有助於預測性和預測性測試的更廣泛採用。人工智慧和生物資訊學等先進資料分析工具的整合正在提高這些測試的效用和準確性，推動其持續成長。這些因素，加上基因檢測技術的持續創新，正在推動預測和預測測試市場的持續成長。

受訪企業範例（14家知名企業）

  • 23andMe, Inc.
  • Abbott Molecular, Inc.
  • BioAxis DNA Research Centre Private Limited
  • Color Genomics, Inc.
  • Direct Laboratory Services LLC（DirectLabs）
  • Gene by Gene Ltd.
  • Genomic Diagnostics
  • Mapmygenome
  • Myriad Genetics, Inc.
  • Pathway Genomics Corporation
  • Positive Bioscience, Inc.
  • Quest Diagnostics, Inc.

目錄

第1章調查方法

第 2 章執行摘要

  • 市場概況
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他亞太地區
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東地區
  • 非洲

第4章 比賽

簡介目錄
Product Code: MCP14178

Global Predictive and Presymptomatic Testing Market to Reach US$10.4 Billion by 2030

The global market for Predictive and Presymptomatic Testing estimated at US$5.5 Billion in the year 2023, is expected to reach US$10.4 Billion by 2030, growing at a CAGR of 9.5% over the analysis period 2023-2030.

The U.S. Market is Estimated at US$1.4 Billion While China is Forecast to Grow at 12.6% CAGR

The Predictive and Presymptomatic Testing market in the U.S. is estimated at US$1.4 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$2.4 Billion by the year 2030 trailing a CAGR of 12.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.5% and 7.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.4% CAGR.

Global Predictive and Presymptomatic Testing Market - Key Trends and Drivers Summarized

Predictive and Presymptomatic Testing: Anticipating Health Risks

Predictive and presymptomatic testing involves the use of genetic and other diagnostic tests to assess an individual's risk of developing a particular disease before symptoms appear. These tests analyze DNA, proteins, and other biomarkers to identify mutations or other indicators that are associated with an increased likelihood of developing conditions such as cancer, heart disease, or neurodegenerative disorders. Predictive testing is typically used in individuals with a family history of a specific disease, allowing for early intervention and preventive measures that can reduce the risk or delay the onset of the disease. Presymptomatic testing, on the other hand, is used to determine whether an asymptomatic individual will develop a genetic disorder that is known to be present in the family. The primary purpose of these tests is to provide individuals and healthcare providers with valuable information that can guide medical decisions and lifestyle changes, ultimately improving health outcomes.

How Are Technological Advancements Enhancing Predictive and Presymptomatic Testing?

Technological advancements have significantly enhanced the accuracy, accessibility, and scope of predictive and presymptomatic testing. Advances in next-generation sequencing (NGS) have made it possible to analyze large segments of the genome quickly and cost-effectively, allowing for the identification of a broader range of genetic variants associated with disease risk. The development of more sensitive and specific biomarkers has improved the ability to detect early signs of disease, even before symptoms emerge. Additionally, the integration of bioinformatics and machine learning algorithms has enhanced the interpretation of genetic data, providing more accurate risk assessments and personalized insights. The rise of direct-to-consumer genetic testing services has also increased access to predictive testing, enabling individuals to gain insights into their health risks without the need for traditional clinical settings. These technological improvements have expanded the applications and impact of predictive and presymptomatic testing, making it a valuable tool for proactive healthcare.

What Are the Key Applications and Benefits of Predictive and Presymptomatic Testing?

Predictive and presymptomatic testing is applied in various areas of healthcare, offering numerous benefits that enhance disease prevention and management. In oncology, predictive testing is used to identify individuals at high risk of hereditary cancers, such as BRCA1/2 mutations associated with breast and ovarian cancer, enabling early surveillance and preventive measures. In cardiology, genetic testing can identify mutations linked to conditions like familial hypercholesterolemia, guiding interventions to prevent heart disease. Neurology benefits from presymptomatic testing for disorders such as Huntington's disease, where early diagnosis can inform family planning and lifestyle choices. Additionally, predictive testing is used in pharmacogenomics to determine how individuals will respond to specific medications, allowing for personalized treatment plans that optimize efficacy and minimize adverse effects. The primary benefits of predictive and presymptomatic testing include the ability to identify disease risks before symptoms appear, enabling early intervention, personalized healthcare, and improved patient outcomes. By providing valuable insights into an individual's genetic predispositions, these tests empower proactive health management and informed decision-making.

What Factors Are Driving the Growth in the Predictive and Presymptomatic Testing Market?

The growth in the predictive and presymptomatic testing market is driven by several factors. The increasing awareness of the role of genetics in disease risk and the growing demand for personalized healthcare are significant drivers, as these tests provide valuable information that can guide individualized treatment and prevention strategies. Technological advancements that enhance the accuracy, speed, and affordability of genetic testing are also propelling market growth. The expansion of direct-to-consumer genetic testing services, which make these tests more accessible to the general population, is further boosting demand. Additionally, the rising focus on preventive healthcare and the early detection of diseases are contributing to the increased adoption of predictive and presymptomatic testing. The integration of advanced data analysis tools, such as AI and bioinformatics, is enhancing the utility and accuracy of these tests, driving their continued growth. These factors, coupled with the ongoing innovation in genetic testing technologies, are driving the sustained growth of the predictive and presymptomatic testing market.

Select Competitors (Total 14 Featured) -

  • 23andMe, Inc.
  • Abbott Molecular, Inc.
  • BioAxis DNA Research Centre Private Limited
  • Color Genomics, Inc.
  • Direct Laboratory Services LLC (DirectLabs)
  • Gene by Gene Ltd.
  • Genomic Diagnostics
  • Mapmygenome
  • Myriad Genetics, Inc.
  • Pathway Genomics Corporation
  • Positive Bioscience, Inc.
  • Quest Diagnostics, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Predictive and Presymptomatic Testing - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Technological Advancements in Genetic Testing Propel Market Dynamics
    • Increasing Awareness of Preventive Healthcare Expands Addressable Market Opportunity
    • Government Initiatives for Genomic Research Strengthens Business Case
    • Growing Adoption of Direct-to-Consumer Genetic Tests Throws the Spotlight on Innovation
    • Focus on Early Disease Detection and Prevention Accelerates Market Demand
    • Expansion of Genetic Counseling Services Boosts Market Prospects
    • Rising Prevalence of Genetic Disorders Enhances Market Growth
    • Integration of AI and Big Data in Genetic Analysis Drives Market Dynamics
    • Increasing Investments in Genomic Research and Development Propels Market Expansion
    • Focus on Reducing Healthcare Costs Sustains Market Growth
    • Growing Use of Predictive Testing in Oncology Expands Market Reach
    • Focus on Regulatory Approvals and Reimbursement Policies Enhances Market Opportunities
    • Rising Consumer Interest in Ancestry and Health Insights Spurs Market Dynamics
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Predictive and Presymptomatic Testing Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Predictive and Presymptomatic Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Predictive and Presymptomatic Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Predictive and Presymptomatic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 5: USA Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 6: USA Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • CANADA
    • TABLE 7: Canada Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 8: Canada Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • JAPAN
    • Predictive and Presymptomatic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 9: Japan Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 10: Japan Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • CHINA
    • Predictive and Presymptomatic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 11: China Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 12: China Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • EUROPE
    • Predictive and Presymptomatic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 13: Europe Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 14: Europe Historic Review for Predictive and Presymptomatic Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 15: Europe 16-Year Perspective for Predictive and Presymptomatic Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • FRANCE
    • Predictive and Presymptomatic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 16: France Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 17: France Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • GERMANY
    • Predictive and Presymptomatic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 18: Germany Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 19: Germany Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • ITALY
    • TABLE 20: Italy Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Italy Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • UNITED KINGDOM
    • Predictive and Presymptomatic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 22: UK Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 23: UK Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • SPAIN
    • TABLE 24: Spain Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 25: Spain Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • RUSSIA
    • TABLE 26: Russia Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Russia Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • REST OF EUROPE
    • TABLE 28: Rest of Europe Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 29: Rest of Europe Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • ASIA-PACIFIC
    • Predictive and Presymptomatic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 30: Asia-Pacific Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 31: Asia-Pacific Historic Review for Predictive and Presymptomatic Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 32: Asia-Pacific 16-Year Perspective for Predictive and Presymptomatic Testing by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • AUSTRALIA
    • Predictive and Presymptomatic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 33: Australia Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 34: Australia Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • INDIA
    • Predictive and Presymptomatic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 35: India Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: India Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • SOUTH KOREA
    • TABLE 37: South Korea Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 38: South Korea Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • REST OF ASIA-PACIFIC
    • TABLE 39: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 40: Rest of Asia-Pacific Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • LATIN AMERICA
    • Predictive and Presymptomatic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 41: Latin America Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 42: Latin America Historic Review for Predictive and Presymptomatic Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Latin America 16-Year Perspective for Predictive and Presymptomatic Testing by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 44: Argentina Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Argentina Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • BRAZIL
    • TABLE 46: Brazil Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 47: Brazil Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • MEXICO
    • TABLE 48: Mexico Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 49: Mexico Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • REST OF LATIN AMERICA
    • TABLE 50: Rest of Latin America Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Rest of Latin America Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • MIDDLE EAST
    • Predictive and Presymptomatic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 52: Middle East Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 53: Middle East Historic Review for Predictive and Presymptomatic Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 54: Middle East 16-Year Perspective for Predictive and Presymptomatic Testing by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
  • IRAN
    • TABLE 55: Iran Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 56: Iran Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • ISRAEL
    • TABLE 57: Israel Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 58: Israel Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • SAUDI ARABIA
    • TABLE 59: Saudi Arabia Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Saudi Arabia Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • UNITED ARAB EMIRATES
    • TABLE 61: UAE Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 62: UAE Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • REST OF MIDDLE EAST
    • TABLE 63: Rest of Middle East Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 64: Rest of Middle East Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • AFRICA
    • Predictive and Presymptomatic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 65: Africa Recent Past, Current & Future Analysis for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Africa Historic Review for Predictive and Presymptomatic Testing by Segment - Predictive and Presymptomatic Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR

IV. COMPETITION